Previous 10 | Next 10 |
home / stock / anpcf / anpcf news
RESEARCH DEMONSTRATES POTENTIAL OF THE PARSORTIX SYSTEM TO SUPPORT POWERFUL CHARACTERISATION OF CTCS IN HEAD AND NECK CANCER 41 key biomarkers including the immune checkpoint proteins PD-L1, CTLA4 and CD39 successfully evaluated Providing key information which could support the developm...
Interim Results for the six months ended 30 June 2023 BUILDING COMMERCIAL MOMENTUM DELIVERS REVENUE GROWTH Cash runway extended into Q1 2025 GUILDFORD, SURREY / ACCESSWIRE / September 7, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative ...
GUILDFORD, SURREY / ACCESSWIRE / June 28, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed. For further information: Notes for editors About ANG...
Brett Swansiger joins as Chief Commercial Officer Karen Miller PhD joins as Chief Scientific Officer GUILDFORD, SURREY / ACCESSWIRE / June 5, 2023 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce the appointments of Br...
Pharma Services Contract Win Parsortix DNA Damage Response Assays developed by ANGLE to be used for exploratory objectives in a Phase 1 clinical trial Trial expected to complete by year end 2024 GUILDFORD, SURREY / ACCESSWIRE / May 25, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a worl...
GUILDFORD, SURREY / ACCESSWIRE / May 22, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company announces that Garth Selvey has informed the Board of his intention to retire and leave ANGLE at the publication of the 2023 Interims in September. Garth will hand over the Cha...
Preliminary Results for the year ended 31 December 2022 FDA CLEARANCE A MAJOR BREAKTHROUGH FOR PARSORTIX LIQUID BIOPS Parsortix system substantially out-performs standard of care for ovarian cancer diagnosis Prostate cancer partnership signed with Solaris Health Pipeline of op...
(NewsDirect) ANGLE PLC (AIM:AGL, OTCQX:ANPCY) chief executive Andrew Newland joins Thomas Warner from Proactive after announcing a development partnership with BioView. The partnership will see the two firms develop to create a circulating tumour cell (CTC) HER2 assay for breast cance...
PARSORTIX POSTER PRESENTED AT AACR ANNUAL MEETING 2023 Study demonstrates the feasibility of combining IF and HER2 FISH analysis with CTCs harvested using the Parsortix system Capability to measure HER2 protein overexpression on CTCs using ANGLE's Portrait Flex assay opens up substantia...
Notice of Preliminary Results and Webcast GUILDFORD, SURREY / ACCESSWIRE / April 3, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its preliminary results for the year ended 31 December 2022 on Friday 21 April 2023. A virtual meeting and we...
News, Short Squeeze, Breakout and More Instantly...
Angle Plc Ord Company Name:
ANPCF Stock Symbol:
OTCMKTS Market:
(NewsDirect) ANGLE PLC chief executive Andrew Newland joins Proactive's Stephen Gunnion with details of a supplier agreement with AstraZeneca PLC to develop an androgen receptor (AR) detection assay to enhance prostate cancer studies. With a contract value of £550,000, the projec...
(NewsDirect) ANGLE PLC chief executive Andrew Newland joins Proactive's Stephen Gunnion with news the company has entered a significant contract with AstraZeneca, marking its second major collaboration with a large pharmaceutical company. Newland, expressed enthusiasm about this devel...
(NewsDirect) ANGLE PLC chief executive Andrew Newland discussed significant advancements in the company's technology, including a European patent for the CellKeep slide, with US intellectual property protection from the US set to follow soon. Newland told Proactive's Stephen Gunnion t...